Sugar cookies sold in 20 states recalled for potential wood contamination: See map
The voluntary recall for the Favorite Day Bakery Frosted Sugar Cookies was issued on July 22 by Give and Go Prepared Foods Corp. in Canada, according to the FDA. Favorite Day is a private label brand sold at Target.
In total, 803 cases are being recalled due to the potential foreign contamination.
The cookies, which could potentially contain wood, were distributed across 20 different states and Washington, D.C., the notice stated.
The recall is classified as a Class II recall, meaning the product "may cause temporary or medically reversible adverse health consequences," according to the FDA.
A press release was not issued for the recall, but as of Sunday, Aug. 10, the recall is ongoing.
Target did not immediately respond to a request for comment from USA TODAY on Aug. 10.
Where were the recalled sugar cookies sold?
The cookies were sold in the following states and districts:
How to tell if you purchased the recalled product
The recalled cookies, Favorite Day Bakery Frosted Sugar Cookies, 10 count, were distributed by Target and produced in Canada.
The cookies are a part of Lot 25195, with the UPC number 85239-41250 3. The packs of cookies have varying Best By Dates, as that is determined by when the retailer removed the cookies from the freezers, according to the notice.
Julia is a trending reporter for USA TODAY. Connect with her on LinkedIn, X, Instagram and TikTok: @juliamariegz, or email her at jgomez@gannett.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
FDA gives Arvinas and Pfizer's vepdegestrant NDA for breast cancer
Arvinas, in collaboration with Pfizer, has announced new drug application (NDA) acceptance for vepdegestrant from the US Food and Drug Administration (FDA) to treat breast cancer. The treatment is aimed at patients with oestrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), oestrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer who have previously undergone endocrine-based therapy. The Prescription Drug User Fee Act (PDUFA) action date is set for 5 June 2026. Vepdegestrant is an investigational, oral bioavailable PROteolysis TArgeting Chimera (PROTAC) medication designed to degrade oestrogen receptors. It is being developed collaboratively by Arvinas and Pfizer as a potential monotherapy option. The submission was based on results from VERITAC-2, a randomised, global Phase III study that compared vepdegestrant against fulvestrant. Patients were randomly assigned in a 1:1 ratio to receive either vepdegestrant, administered orally once daily on a continuous 28-day schedule, or fulvestrant, which was given intramuscularly. 43% of the patients in the trial had detectable ESR1 mutations. Progression-free survival (PFS), measured both in patients with ESR1 mutations and across all trial participants, served as the primary endpoint evaluated through blinded independent central review. Overall survival (OS) remains an important secondary endpoint. Arvinas chairperson, CEO and president John Houston stated: 'Patients often face limited treatment options after first-line treatment and vepdegestrant demonstrated improved progression-free survival in patients with ESR1-mutated ER+/HER2- advanced breast cancer. 'With the efficacy and favourable tolerability seen in VERITAC-2, we believe vepdegestrant, if approved, has potential to be a best-in-class treatment option for patients in the second-line ESR1-mutant setting.' In August 2025, Pfizer raised its full-year profit forecast, driven by robust sales of its heart disease medication Vyndaqel (tafamidis) and the blood thinner Eliquis (apixaban), among other products. "FDA gives Arvinas and Pfizer's vepdegestrant NDA for breast cancer" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
2 hours ago
- Yahoo
GSK climbs after winning FDA priority review for oral gonorrhoea antibiotic
-- GSK (NYSE:GSK) (LON:GSK) said on Monday that the U.S. Food and Drug Administration has accepted its priority review application for gepotidacin, an oral antibiotic aimed at treating sexually transmitted uncomplicated gonorrhoea. The drugmaker's shares climbed 1% in London on the news. The company is looking to new infectious disease products, including its recently launched respiratory syncytial virus vaccine, to offset expected revenue declines from top-selling medicines and looming patent expirations in its HIV portfolio. Gepotidacin is already approved in the U.S. under the brand name Blujepa for treating a common urinary tract infection in women and adolescent girls. The FDA is expected to decide in December on its use for uncomplicated urogenital gonorrhoea, which could offer patients an oral alternative to existing injectable treatments. Separately, GSK and Germany's CureVac last week resolved a long-running patent dispute with Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) over mRNA vaccine technology used during the COVID-19 pandemic. The settlement follows BioNTech's June agreement to acquire CureVac in an all-stock deal worth $1.25 billion to advance work on mRNA-based cancer therapies. Under the settlement, CureVac and GSK will receive $740 million and single-digit percentage royalties on future U.S. sales of COVID-19 vaccines, CureVac said. GSK's share amounts to $370 million, including $50 million to adjust terms from a 2024 licence agreement that expanded their pandemic-era partnership. If BioNTech's takeover of CureVac is completed, related mRNA litigation outside the U.S. will also be resolved, with GSK receiving an additional $130 million and royalties extended to non-U.S. sales. CureVac said the acquisition remains on track under the agreed terms. GSK said it still has separate patent cases against Pfizer and BioNTech in the U.S. and Europe, which are unaffected by this settlement. Related articles GSK climbs after winning FDA priority review for oral gonorrhoea antibiotic USPS blocks major vape distributor over unregulated product shipments - Reuters Exclusive: Opendoor CEO Wheeler breaks silence, EMJ's Eric Jackson calls for more Sign in to access your portfolio
Indianapolis Star
5 hours ago
- Indianapolis Star
Sugar cookies sold in 20 states recalled for potential wood contamination: See map
Hundreds of cases of sugar cookies sold at Target are being recalled for potential contamination by a "foreign material," according to a notice posted to the Food and Drug Administration's website. The voluntary recall for the Favorite Day Bakery Frosted Sugar Cookies was issued on July 22 by Give and Go Prepared Foods Corp. in Canada, according to the FDA. Favorite Day is a private label brand sold at Target. In total, 803 cases are being recalled due to the potential foreign contamination. The cookies, which could potentially contain wood, were distributed across 20 different states and Washington, D.C., the notice stated. The recall is classified as a Class II recall, meaning the product "may cause temporary or medically reversible adverse health consequences," according to the FDA. A press release was not issued for the recall, but as of Sunday, Aug. 10, the recall is ongoing. Target did not immediately respond to a request for comment from USA TODAY on Aug. 10. The cookies were sold in the following states and districts: The recalled cookies, Favorite Day Bakery Frosted Sugar Cookies, 10 count, were distributed by Target and produced in Canada. The cookies are a part of Lot 25195, with the UPC number 85239-41250 3. The packs of cookies have varying Best By Dates, as that is determined by when the retailer removed the cookies from the freezers, according to the notice.
